Company / Revenue
ALNYLAM PHARMACEUTICALS, INC. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$3.7B
FY2025
5-year range
$219.8M / $3.7B
FY2021-FY2025
Trend
+65.2%
vs FY2024
Sector context
#23 of 155
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s revenue of $3.7B is higher than 85% of companies in the Health Care sector (FY2025). Revenue has increased for 5 consecutive years, from $75M in FY2020 to $3.7B in FY2025.
Based on SEC 10-K filings.
$3.7B in FY2025 with a 5-year CAGR of +118.3%. Top quartile in the Health Care sector.
Improved from $1.8B to $3.7B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +96.1%
- 5-Year CAGR
- +118.3%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 155This company $3.7B Sector average $4.5B
▼
-16.9% below sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s revenue has grown for 5 consecutive years.
- 5-year CAGR of +118.3%, indicating consistent growth.
- In FY2025, revenue increased 65.2% year-over-year.
- Ranks #23 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.7B | +65.2% |
| FY2024 | $2.2B | +23.0% |
| FY2023 | $1.8B | +271.0% |
| FY2022 | $492.9M | +124.3% |
| FY2021 | $219.8M | +193.4% |
| FY2020 | $74.9M | -16.7% |
| FY2019 | $89.9M | +90.7% |
| FY2018 | $47.2M | -47.5% |
| FY2017 | $89.9M | +90.7% |
| FY2016 | $47.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026